Hospital M&A activity expected to continue brisk pace in 2018

If the first quarter of the year is any indication, the frantic pace of mergers and acquisitions (M&A) among hospitals won’t be slowing down in 2018. Thirty transactions were announced between January 1 and March 31, an 11 percent increase over the same period in 2017, according to Kaufman Hall.

The “staggering” increase in the scale of hospital mergers seen in 2017 has continued into this year, the quarterly M&A report said, with three deals involving systems with more than $1 billion in revenue and another four including organizations with revenue of between $500 million and $1 billion. As consolidation among hospitals continues abated and vertical integrations like the Aetna-CVS and Cigna-Express Scripts deals threaten traditional providers’ bottom lines, hospitals are looking to scale up to survive.

“Greater scale enables health systems to build the tangible and intellectual capital required to secure the resources they need to transform traditional business models from an economic and service standpoint,” said Anu Singh, managing director at Kaufman Hall. “Without such scale, legacy hospitals and health systems are going to find it difficult, if not impossible, to stay competitive in markets with these new entrants and emerging mega-systems.”

The largest deal of the quarter was the merger of two Catholic health systems, Maryland’s Bon Secours and Cincinnati’s Mercy Health. If completed, the systems would combine in a 43-hospital chain with $8 billion in annual revenue serving seven states across the eastern half of the U.S.

Other major deals announced were Einstein Healthcare Network joining the 14-hospital Jefferson Health and for-profit giant HCA acquiring not-for-profit Mission Health. HCA’s transaction is becoming less common, the report said, as not-for-profit providers are more often the larger entity in these deals while other for-profit systems look to divest of facilities as they deal with decreases in same hospital patient revenue.

“Large for-profit and not-for-profit health systems continue to reposition their operations to increase market access in regions of strategic interest, while rationalizing, downsizing, and even exiting markets where there is not a path to relevance over the long term,” Singh said. “These moves reinforce the shift from the financial to the strategic rationale of most partnership activity. At least in this dimension, the distinction between for-profit and not-for-profit is dwindling.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.